Radiation-associated angiosarcoma of the breast: An international multicenter analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10440744" target="_blank" >RIV/00669806:_____/22:10440744 - isvavai.cz</a>
Alternative codes found
RIV/00216275:25520/22:39918703 RIV/00843989:_____/22:E0109497 RIV/00098892:_____/22:10157312 RIV/00064165:_____/22:10440744 and 5 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=01e-w0pBZ8" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=01e-w0pBZ8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.suronc.2022.101726" target="_blank" >10.1016/j.suronc.2022.101726</a>
Alternative languages
Result language
angličtina
Original language name
Radiation-associated angiosarcoma of the breast: An international multicenter analysis
Original language description
Introduction: Radiation-associated angiosarcoma (RAAS) is a rare and serious complication of breast irradiation. Due to the rarity of the condition, clinical experience is limited and publications on this topic include only retrospective studies or case reports. Materials and methods: All patients diagnosed with RAAS between January 2000 and December 2017 in twelve centers across the Czech Republic and Slovakia were evaluated. Results: Data of 53 patients were analyzed. The median age at diagnosis was 72 (range 44-89) years. The median latency period between irradiation and diagnosis of RAAS was 78 (range 36-172) months. The median radiation dose was 57.6 (range 34-66) Gy. The whole breast radiation therapy with radiation boost to the tumor bed was the most common radiotherapy regimen. Total mastectomy due to RAAS was performed in 43 patients (81%), radical excision in 8 (15%); 2 patients were not surgically treated due to unresectable disease. Adjuvant chemotherapy followed surgical therapy of RAAS in 18 patients, 3 patients underwent adjuvant radiotherapy. The local recurrence rate of RAAS was 43% and the median time from surgery to the onset of recurrence was 7.5 months (range 3-66 months). The 3-year survival rate was 56%, the 5-year survival rate was only 33%. 46% of patients died during the follow-up period. Conclusion: The present data demonstrate that RAAS is a rare condition with high local recurrence rate (43%) and mortality (the 5-year survival rate was 33%.). Early diagnosis of RAAS based on biopsy is crucial for treatment with radical intent. Surgery with negative margins constitutes the most important part of the therapy; the role of adjuvant chemotherapy and radiotherapy is still unclear.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30212 - Surgery
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Surgical Oncology
ISSN
0960-7404
e-ISSN
1879-3320
Volume of the periodical
41
Issue of the periodical within the volume
May
Country of publishing house
GB - UNITED KINGDOM
Number of pages
8
Pages from-to
101726
UT code for WoS article
000789993900010
EID of the result in the Scopus database
2-s2.0-85124891328